ESPE Abstracts

Objective: To determine the effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on auxological outcome of Korean boys with central precocious puberty (CPP) and early puberty (EP).

Methods: This study included 11 boys with CPP and 8 boys with EP who were treated with GnRHa for at least 2 years at the Pediatric Endocrine Unit of Ajou University Hospital from March 2003 to December 2015. All nineteen boys attained final adult height (FAH). Anthropometry, bone age, sexual maturity rating, and predicted adult height (PAH) were assessed every 6 months. We compared their FAH with their initial predicted adult height (PAH). Moreover, we performed a multivariate analysis of the factors associated with FAH.

Results: Mean chronological age (CA) and bone age (BA) of patients in CPP at the start of treatment were 9.32 ± 0.78 years and 12.41 ± 1.02 years, respectively. Mean duration of treatment was 2.7 ± 0.6 years. Their PAH at the start of treatment was 166.7 cm (-1.18 ± 1.33, PAH standard deviation score [SDS]). The mean FAH in boys with CPP was 172.05 ± 6.49 cm and their FAH was significantly increased compared to their pretreatment PAH (p = 0.043). Mean CA and mean BA of patients in EP at the start of treatment were 10.98 ± 0.47 years and 13.0 ± 0.59 years, respectively. Their PAH at the start of treatment was 170.46 ± 4.85 cm (- 0.51 ± 0.87, PAH SDS) in EP. The mean FAH in boys with EP was 171.9 ± 4.63 cm and there was no significant difference between initial PAH and FAH in EP. The FAH was only significantly correlated with initial height before treatment.

Conclusion: The FAH was significantly higher than the initial PAH in boys with CPP who were treated with GnRHa.